To consider using ConnecTrial sites for a study, click “contact us” to send us an email. Ideally, you would forward a study synopsis and site questionnaire for the study. If no synopsis is available, simply provide a few sentences describing the study, with emphasis on patient inclusion/exclusion criteria that will impact enrollment, i.e., information that will help a site determine if they have the right patient population for the study.
We will survey our sites and find out which sites are generally interested in the study. We do not use Sponsor/CRO or drug names during this initial survey. We then share the synopsis and questionnaire with the interested sites. Usually, 4-6 sites are interested in any given study.
Finally, we will return the completed questionnaires to you, along with other information like physician CV’s, if requested.
Confidential Disclosure Agreement (CDA) Information
If CDA’s are required, we follow the same process outlined above, but we put CDA’s in place with interested sites before sharing any information.
As a first step, Sponsors/CRO’s generally find it easiest to first put a CDA in place with ConnecTrial, then put CDAs in place with each interested site. You may forward us a template CDA and we will manage getting them completed. Or, we can provide you with site information and you can handle CDA’s directly.
ConnecTrial’s CDA information is:
ConnecTrial Corporation
5208 Card St
McFarland, WI 53558
608-579-1672
608-579-1673 (fax)
CDA will be signed by: Douglas Dillman, CEO